WBC
PCVX icon

West Branch Capital’s Vaxcyte PCVX Stock Holding History

West Branch Capital’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-135
Closed -$7.84K – 377
2026
Q1 		$7.84K Hold
135
– – ﹤0.01% 245
2025
Q4 		$6.23K Hold
135
– – ﹤0.01% 297
2025
Q3 		$4.86K Hold
135
– – ﹤0.01% 332
2025
Q2 		$4.39K Hold
135
– – ﹤0.01% 339
2025
Q1 		$5.1K Buy
+135
New +$10.8K ﹤0.01% 344

Other funds holding PCVX

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

West Branch Capital's PCVX Position: Q2 2026 in Review

West Branch Capital sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 135 shares — an estimated $7.84K sold.

West Branch Capital first reported a position in PCVX in Q1 2025 and held it in 5 quarters. The position peaked at $7.84K in Q1 2026. 79 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • West Branch Capital reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
  • West Branch Capital sold 135 Vaxcyte shares in Q2 2026, an estimated $7.84K.
  • West Branch Capital first reported a position in Vaxcyte in Q1 2025 and held it in 5 quarters.
  • West Branch Capital's Vaxcyte position peaked at $7.84K in Q1 2026.
  • 79 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on West Branch Capital's 13F filing for Q2 2026, filed 10 Jul 2026.